Induced systemic hypothermia in asphyxiated new-born
infants: a randomized, controlled, multicenter study
Appendix 1: Procedures and definitions for neurological assessment,
aEEG and EEG assessment
Appendix 2: Scientific basis for inclusion criteria, classification into sub-
groups and sample size calculations
Appendix 3: Specifications for cooling mattress and aEEG device
Appendix 4: Monitoring schedule
Appendix 5: Case Record Form
Principal Investigator and Organizer:
Simbruner G, M.D., Professor of Pediatrics
Division Neonatology, University Childrens´s Clinic,
35 Ludwig-Maximilians University, Munich
Lindwurmstraße 4, D - 80337 Munich, Germany
Fax : + 49 89 5160 - 4419 ;
e-mail > firstname.lastname@example.org
3 May 2000
Study protocol :
45 Induced systemic hypothermia in asphyxiated new-born infants:
a randomized, controlled, multicenter study.
Participants in Germany and other European Countries within the framework of the
”neo-nEuro-network” (abbreviated n.n.n), an non-juridal association of neonatologists
interested in neurological and neuro-intensive care investigations.
Simbruner G, Division Neonatology, Ludwig-Maximilians University, Munich
Fax : + 49 89 5160 - 4419 ; e-mail > email@example.com
Scientific Committee of the nnn Hypothermia Study:
Blennow M, Huddige Hospital , Huddige, Sweden,
Gaus W, Univ Ulm, Ulm, Germany
65 Greisen G, Univ Copenhagen, Copenhagen, Denmark
Obladen M, Charite, Humboldt Univ, Berlin, Germany
Pohlandt F, Univ Ulm, Ulm, Germany
Simbruner G, LMU, Munich,Germany
Thoresen M, Univ Bristol, Bristol , UK
70 Zupan V, Univ Paris, Paris, France
W. Gaus, Department of Biometry and Medical Documentation
75 University of Ulm, Germany
Fax: +49 731 50-26902; e-mail: firstname.lastname@example.org
Regional co-ordinators (Status 12 April, 2000):
80 Copenhagen, Denmark: Gorm Greisen
Munchen, Germany: Georg Simbruner
Paris, France: Veronique Zupan
85 Acknowledgement :
We thank the principal investigator Peter D Gluckman, Auckland, New Zealand of the
Olympic Medical Brain Cooling Trial and Olympic Medical for providing a copy of that
protocol. Inclusion and exclusion criteria and the primary endpoint is identical in the two
protocols. The brain cooling trial uses a cooling cap and a target body temperature of
90 34.5°C whereas we will use systemic cooling to 33.5°C and all patients receive mor-
phine for pain and sedation. We think that the results from the two trials can add up to
document a potential benefit of hypothermia as well as suggest a difference between
the two approaches. I thank Professors Azzopardi D and Edwards DA for also providing
insight into their study protocol.
This randomized, controlled multicenter study aims to determine whether inducing sys-
100 temic hypothermia in birth-asphyxiated new-born infants born at term increases the
chance of survival without severe neurodevelopmental handicap. Secondary objectives
are to determine whether the treatment benefit is greater in milder rather than more se-
vere asphyxia, and whether systemic hypothermia is associated with significant side-
New-born infants with a gestational age of > 36 weeks , asphyxiated at birth, who show
evidence of encephalopathy and who have abnormal EEG within 6 hrs of postnatal age,
will be randomized to hypothermia or to normothermia. Hypothermia (target rectal tem-
perature 33.5°C) will be induced by a cooling matters, perfused with water. Hypother-
110 mia will be maintained for 72 hours. Infants in both groups will receive morphine at a
sedative and analgesic dosage.
Neurological assessment will be done at 7 days, 6 and 18 months. Further, at
18 months the Griffith General Quotient will be assessed. The primary outcome is (1)
115 death, or (2) inability to sit unsupported, or (3) Griffith GQ < 85, or (43) bilateral cortical
blindness at 18 months or a combination thereof. The statistical analysis will examine
whether the hypothermia and control group differ in their proportion of infants surviving
without disability .
Severe birth asphyxia results in brain damage and death or lifelong handicap. The sci-
125 entific community so far failed to provide an effective protective or therapeutic interven-
Controlled mild hypothermia is the best candidate for a post-asphyxia intervention. Hy-
pothermia has been proven effective in several animal species.
Extensive clinical experience with short term, deep hypothermia exists from heart sur-
130 gery practice. Some clinical experience exists with long-term moderate hypothermia. Al-
though hypothermia may have side effects, even if serious, they are likely to be acute,
whereas the benefits are likely to be long term.
It is therefore reasonable to proceed to a randomized controlled trial. A trial of selective
head cooling is under way in New Zealand, USA, Canada and the UK. The present
135 protocol is sufficiently similar and sufficiently different to the Olympic Medical Head
Cooling Trial to be likely to add significantly to the evidence provided by that study.
The major ethical concern is the limited possibility to obtain truly informed, free consent
by the parents. There is no solution to this problem. It will be the duty of the investiga-
tors to remain sensitive to parental wishes, to obtain the best possible consent, and to
140 offer a high level of information to the parents throughout the study.
The incidence of asphyxiated full-term infants still ranges between 2 and 4 infants per
145 1000 deliveries in high income countries (1, 2) and may be significantly higher in low
income countries. Birth asphyxia results in longterm neurological sequelae in up to 20%
of infants, if moderate and in up to 100% of infants, if severe. Birth asphyxia causes
high costs for posthospital care and severe suffering of families (3, 4).
150 Systemic and selective hypothermia.
From animal experiments a vast body of knowledge demonstrates that a low intra-
ischemic brain temperature or lowering brain temperature by 2-4 °C post ischemia may
protect the asphyxiated brain from neuronal damage and cell death and improve long
term neurological outcome (5-7, 47). In factually all animal experiments, hypothermia of
155 the brain was induced and associated with hypothermia of the rest of the body. Selec-
tive brain cooling while maintaining normal rectal temperature was demonstrated to be
possible in new-born piglets (8), but evidence of long lasting effects or superiority to
systemic hypothermia is still lacking.
In analogy, all human hypothermia studies in adults were based on systemic body
160 cooling. Mellegard P. demonstrated that effective selective cooling of the brain was not
possible in adult neurosurgical patients (9). Simply heat balance calculations or complex
mathematical model indicate, that selective brain cooling is only possible if one accepts
extreme temperature gradients across both, body and
170 Hypothermic interventions have five domains which appear to determine the balance
between protective and adverse effects: (1) temperature range of and profile within
brain tissue, (2) time relation of occurrence of insult to inducing hypothermia, (3) dura-
tion of cooling, (4) degree of severity of the neuronal injury, and (5) developmental and
biological age of the individuum subjected to hypothermia.
Though a controversial issue, most animal studies suggest, that the optimal brain tem-
perature for neuroprotection ranges between 32 and 34 °C. In some studies mild hypo-
thermia (34°C) was found to mitigate neuronal damage to a larger extent than moder-
180 ate (32 - 28°C) or deep hypothermia (28 - 17°C) (11,12). In other studies, mild hy-
pothermia was as effective in reducing biochemical and histological markers of neuronal
injury and in reducing abnormal behaviour (12 - 15).
Time relation between insult and hypothermia.
185 Hypoxic-ischemic injury resulting in encephalopathy evolves in two phases , the primary
and secundary energy failure. The primary event triggers a series of biochemical and
immunological responses which are responsible for the pathophysiology of the second
phase and for the final manifestation of cerebral damage. These biochemical and im-
munologic responses include release of cytotoxic neurotransmitters (13), oxygen radi-
190 cals (16), inflammatory mediators and signals inducing apoptosis (17). It appears natu-
ral that an immediate or earlier intervention might be more successful than delayed
ones. In animal experiments, hypothermia induced at 1 to 5.5 hours were more effective
compared to later inductions (14,18 -20). The neuroprotective effects diminishes and
disappears if cooling is delayed beyond 6 hours (14, 20)
Duration of hypothermia.
Duration of cooling clearly relates to short and long term outcome of asphyxia (7, 14,
20), longer periods being more effective than shorter periods of hypothermia. The dura-
tion of hypothermia ranges up to 72 hours in asphyxiated animals, kept at 35°C (20).
200 In human trauma patients a hypothermia of about 33°C was applied for 24 hours (21).
Asphyxiated human new-borns have been kept at a rectal temperature of 35.5 °C for
72 hours (22) and at a nasopharyngal temperature of 34.5° for an average of 78 hours
205 Severity of the injury and developmental stage of the injured.
Scarce data in animal and human studies indicate that the neuroprotective impact of
hypothermia is stronger in mild than severe neuronal injury (18, 21, 24). Few and con-
troversial studies are available which investigated the effectiveness of hypothermia on
neuroprotection in dependence of developmental age (25, 26). However, in rats of vari-
210 ous developmental stages, brains of immature rats were found to be less resistant to
hypoxia (26). The neonatal brain undergoes drastic neuronal remodelling through
apoptosis before and after birth. Different remodelling and healing capacity in develop-
ing individuals might be responsible for the fact, that similar therapeutic procedures like
ECMO generally produce better outcome result in new-born infants than in pediatric or
215 adult patients (see ECMO registry).
220 Hypothermia on one hand can be the manifestation of an underlying disease and on the
other hand the result of an accidental or actively induced heat loss. Hypothermia causes
a wide spectrum of effects on all organ systems. We suggest to classify these effects
into (i) physiological changes, which are reversible. Amongst them, low heart and
breathing rate immediately reverse to normal, when normothermia is reinstituted , (ii)
225 pathologic alterations, which are reversible, probably represent some health risks, but
have not shown to result in irreversible damage, either without or with treatment .
Amongst them hypoglycemia, altered coagulation states or low platelets, and (iii) altera-
tions which result in irreversible damage despite attempts of or due to lack of effective
treatments, amongst them occurrence of intracranial tissue bleeding or untreatable car-
230 diac arrest due to arrhythmias (although arrhythmias are not reported to occur at mild
hypothermia). Difficulties in assessing the hypothermic effects arise from possible com-
binations of causes, their manifestations and their consequences.
Accidental hypothermia and hypothermia, caused by disease or therapy, is known to
235 affect factually all organ systems (27, 28). Some of these effects are reversed at nor-
mothermia without causing disease or impairment. Other effects like arrhythmias, co-
agulation disorders or infections may have long term sequelae (29 - 34). Accidentally
cooled prematures with a rectal temperature < 34 °C at admission suffered from co-
agulation disorders, a high incidence of hemorrhage and mortality, whilst another group
240 of newly born prematures with an average rectal temperature of 31 ± 2.7 °C at admis-
sion exhibited only transient thromobcytopenia and renal failure (31,32).
In controlled clinical trials on adult trauma or cardiac arrest patients , induced mild to
moderate hypothermia for up to 24 hours resulted in some beneficial effects (21,35, 36)
245 without any significant, irreversible side-effects. In a study by Metz et al. on ten trauma-
tized adults, subjected to moderate hypothermia for 24 hours, adverse effects such as
temporary decrease of cardiac index, thrombocytes and creatinine clearance, and an
elevated serum lipase activity were reported (37).
250 Whole body cooling had been applied to asphyxiated mature human new-borns after
delivery by Westin (38) in the sixties. Several trials treating asphyxiated term infants
with hypothermia followed without reporting details on immediate effects or complica-
tions (39). Head cooling in 12 asphyxiated new-borns to two temperature levels (six at
36.5-36.0°C and six at 35.5 - 35.9°C) was reported not to result in any adverse effects
255 which could be specifically attributed to hypothermia (22). Incidences of adverse side
effects in asphyxiated new-borns cooled to 34.5° nasopharyngeal temperature for 3 1/2
days were not different from those asphyxiated but kept at normal body temperature
260 A randomized, controlled study on the effect of mild hypothermia (two arms: control vs.
head cooling method) is in process by Gluckman & Wyatt in cooperation with Olympic
Medical , Seattle, USA with the following known characteristics:
1) Hypothermia induced by external head cooling (cooling cap Olympic Medical)
2) Hypothermia maintained for three days
265 3) Inclusion of moderate and severe cases of asphyxia (aEEG < 5 uVolt) with an esti-
mated chance of death or disability of 80%
4) Regulatory endpoint Trectal 34. 5± 0.5 °C
5) Study endpoint : combined rate of mortality and neurodevelopmental
impairment at 18 month of age.
This study will differ from the one of Gluckman & Wyatt in the following respects:
1) Systemic cooling without any efforts to achieve a temperature difference between
head and rest-of-the body by cooling the head and to add radiative heat to the
275 2) Regulatory end-point is T rectal 33-34°C, a mean of 33.5 °C
3) Routine analgesia and sedation in both groups with morphine.
4) Prospectively planned assessment of treatment effect in mild to moderate vs.
5) Option of cooling before transport
280 6) Trectum measured at 2-3 cm from anus, thus allowing measurements with
ubiquitous available rectal thermometers.
The objectives of this randomized, controlled, multicenter study are 1) to determine
whether inducing systemic hypothermia in birth asphyxiated new-born infants at term
decreases the proportion of infants who die or survive with severe neurodevelopmental
handicap when compared to new-born infants whose body temperature is maintained
290 within the normal range, 2) to determine whether the protective effect of hypothermia is
related to the severity of asphyxia and 3) to evaluate the safety of hypothermia.
295 Primary: Hypothermia at 33-34°C, induced by a cooled mattress for three days in se-
verely asphyxiated new-born infants, reduces the risk of death or severe neurodevelop-
mental handicap at 18 - 21 months.
Secondary (a): Hypothermia reduces neurodevelopmental retardation (measured by
300 Griffith GQ) at 18 - 21 months to a significant larger extent in the group with moderately
abnormal EEG compared to the group with severely abnormal EEG.
Secondary (b): Systemic hypothermia in the range 33-34°C for 72 hours is safe.
1. Randomized, controlled, multicenter trial with blinded assessment of
310 neurodevelopmental outcome.
2. The protocol and data acquisition is designed to provide a common minimal
dataset to test the primary and two secondary hypotheses by participation of
regional study groups. The common statistical analysis will be carried out by Prof.
W. Gaus, Department of Biometry and Medical Documentation, University of Ulm,
3. Statistical analysis will be based on intention-to-treat.
4. Safety and interim analyses at 1/4, 1/2 and 3/4 of patient recruitment in a fixed
sample design. A safety monitoring committee will be headed by Prof. F Pohlandt,
Dept of Paediatrics, University of Ulm, Germany. Severe adverse events, likely to
320 be related to hypothermia must be reported to the Department of Biometry and
Medical Documentation, University of Ulm, Germany, by fax on the same day.
5. Regional co-ordinators are responsible for data quality. As a minimum, all entries
in patient record forms must be dated and signed, and all participating centers
must be visited by a regional monitor once per year when a sample of case record
325 forms must be checked against patient charts. This quality control must be
6. Inclusion of new patients must be reported to the regional co-ordinator by fax on
the same day.
7. Individual centres are encouraged to add on studies provided this does not
330 interfere with the objectives of this protocol.
8. Centres involved in testing of new, unproven and unpublished neuroprotective
strategies for asphyxiated infants cannot participate in the study.
9. Publication will be in the name of ‘neo-nEuro-network’ with a detailed
acknowledgement of all contributions.
335 10. Publication of add-on studies can be done as relevant with the mention of the par-
ticipation in the neo-nEuro-network. Statistics which can be used to test the
hypotheses of this protocol must be avoided.
340 PATIENT SELECTION
6.1 Inclusion Criteria
The infant will be assessed sequentially by criteria A, B and C listed below:
A. Evidence of severe birth asphyxia in infants >36 weeks gestation admitted to the
NICU: ONE of the following
345 υ Apgar score of < 5 at 10 minutes after birth
υ Continued need for resuscitation, including endotracheal or mask ventilation, at
10 minutes after birth
υ Acidosis defined as either umbilical cord pH or any arterial pH within 60 minutes
of birth <7.00
350 υ Base Deficit ≥ 16 mmol/L in umbilical cord blood sample or any blood sample
within 60 minutes of birth (arterial or venous blood)
B. Evidence of encephalopathy (assessed by certified study personnel): Moderate to
severe encephalopathy consisting of altered state of consciousness: lethargy,
stupor or coma, and at least one or more hypotonia, abnormal reflexes including
355 oculomotor or pupillary abnormalities, an absent or weak suck or clinical seizures.
C. Evidence of moderate-to-severe neurophysiological dysfunction: At least 30 minutes
duration of amplitude integrated EEG or standard EEG recording that shows abnor-
mal background EEG activity or seizures (see definitions : Appendix 1). The aEEG
or EEG may be performed from one hour of age. aEEG or EEG should be read by
360 certified study personnel. Classification of the aEEG is according to al Naqeeb et al.
(42). The classification of the EEG is according to Lamblin et al (45). The aEEG or
EEG 30 min following IV anticonvulsant therapy, e.g. phenobarbitone should not be
used for classification.
365 υ Infants expected to be >5.5 hours of age at the time of randomization.
υ Prophylactic administration of high dose anticonvulsants (e.g. >20mg/kg phenobar-
bitone). After trial entry phenobarbitone or other anticonvulsant therapy may be
given as clinically indicated to treat seizures (see co-treatment below).
υ Major congenital abnormalities, such as diaphragmatic hernia requiring ventilation,
370 or congenital abnormalities suggestive of chromosomal anomaly or other syn-
dromes that include brain dysgenesis.
υ Imperforate anus (since this would prevent rectal temperature recordings).
υ Evidence of head trauma or skull fracture causing major intracranial hemorrhage.
υ Infants <1,800 g birth weight.
375 υ Head circumference <(mean−2SD) for gestation if birth weight and length are
υ Infants ”in extremis” (those infants for whom no other additional intensive manage-
ment will be offered in the judgement of the attending neonatologist). Record in de-
tail reason for exclusion.
380 υ Overt bleeding
If all inclusion and no exclusion criteria are met, the infants are eligible for randomiza-
Recording and Classification of aEEG or standard EEG (Appendix 1)
390 The aEEG will be recorded with a Lectromed Cerebral Function Monitor and the use of
needle electrodes inserted at an exact distance of 5 cm apart from each other at the
parietal regions. The recording speed is 1mm/min. The classification of the aEEG is
based on the publication of Niran al Naqeeb et al. (ref 42 : Pediatrics 1999; 103;
1263-1271) which yields two subgroups: Moderately abnormal aEEG designates mildly
395 to moderately asphyxiated new-borns and suppressed aEEG severely asphyxiated
new-borns. This classification is used for subgroup analysis.
The standard EEG is recorded according to the International 10-20 Classification. The
classification of the EEG is based on the publication of Lamblin MD et al. (ref 45: Neu-
400 rophysiol Clin 1999; 29: 123 - 219)
405 Randomisation is done after informed consent from at least one parent. Consent may
be written or verbal and documented by a wittness.
Entry criteria and other parts of the minimal data set is entered in the Case Record
All infants are nursed in an open care unit (cot, radiant heater unit, bed etc). If relevant,
415 randomisation may be done in a local hospital and treatment started and continued
during transfer to a study center, provided temperature control and documentation is
Body temperature is measured rectally, at least 2 cm from the anus, preferentially with a
420 permanent probe .
Infants randomized to the control group are treated according to present standards of
425 postnatal care with the aim of achieving a normal body temperature i.e. T rectum of 37°C
(range: 36.5 to 37.5°C) . All handling and treatments otherwise should be identical to
the one of the hypothermia group.
Infants randomised to the hypothermia group will be nursed naked on a cooling mat-
tress (cooling device and matrass see: Appendix 3) which is perfused by circulating
water at a variable temperature and covered by normal linen. The infant will have a dia-
per around the lower half of the abdomen. The rectal temperature is targeted at 33.5
435 °C (range of 33 to 34 °C). The duration of hypothermia is 72 hours.
Induction of hypothermia
Target temperature should be achieved within 60 min. The water temperature should
440 initially be set to 10°C. The body temperature should be checked every 10 min. If the
temperature drop is insufficient the cooling mattress should be wrapped around the in-
fant or cool packs be applied.
Normally a mattress temperature of 32-33°C will maintain the temperature within
range. The temperature must be recorded every hour. Be prepared to reduce matters
temperature in case of seizures, to increase it at initiation of mechanical ventilation etc.
Rewarming is started by stopping the cooling of the mattress. Check the temperature
every hour. The infant should reach a normal rectal temperature in 6 -12 hours after
stopping cooling. If the infant does not warm up spontaneously, heat may be added
455 from a radiant heater. Check the temperature more frequently. If the temperature rises
more than 0.5°C per hour, the cooling mattress should be used to control the rise.
460 Temperature is managed according to routine care. Beware of rebound hypothermia.
465 1. All infants in the hypothermia and control group will receive morphine at 0.1 mg/kg
every 4 hours during the first three days as brain edema might and as cold does
induce discomfort, restlessness, anxiety and irritation (References: in Physiological
and Behavioral Temperature Regulation. Chapter 57. Eds. Hardy JD, Gagge AP,
Stolwijk JAJ, 1970 Charles C Thomas Publisher) and pain (Reference: Maria Fitz-
470 gerald, London, at 11 Anual ESIC Congress, Stockholm, 1998). Hypothermia in-
creases stress hormones (48).
2. In ventilated infants PCO2 should be maintained between 40 and 60 mmHg. In
spontaneous breathing infants hyperventilation will not be treated, but hypoventi-
lation with PCO2 > 60 mmHg will be treated.
475 3. All other treatments will be given according to clinical routines
Discontinuing hypothermia before 72 hours
1. Parents withdraw consent.
480 2. The attending neonatologist decides, if possible after consultation with the regional
co-ordinator (Record reason for withdrawal). Potential reasons might include for
example bleeding, thrombosis, pulmonary hypertension or arrhythmia which is
difficult to control, or continued inability to maintain rectal temperature in the
485 3. Need for ECMO.
If hypothermia is discontinued prior to 72 hours, rewarming will be done according to
clinical routine. The follow-up procedures will be done unless the parents withdraw their
permission for this.
Improvement on continuous aEEG or standard EEG recording, after trial entry, is not an
490 indication for discontinuing treatment.
7 ± 1 days postnatal : Neurological assessment by the Thompson score
495 (ref. 41) and brain ultrasound.
6 months: Bodyweight, length, and head circumference and gross neurological as-
sessment (blinded assessment by certified study personnel).
500 12 months: Parental questionnaire.
18 month: Neurological examination and determination of Griffith General Quotient
(GQ) (blinded assessment by certified study personnel). Persistent neurological signs
consistent with a central motor deficit are classified according to five level classification
505 of Palisano et al (40).
Primary Outcome Measure
Survival at 18–21 months of postnatal age free of severe neurodevelopmental handi-
Severe neurodevelopmental handicap is defined as one or more of
515 ← Neurological deficit with a functional score of 3-5 as defined by Palisano et al. (40),
i.e. sitting only with low back support or worse.
← Griffith General Quotient of less than 85 (i.e. < 2 SD)
← Severe bilateral cortical visual deficit (no reaction to a threat to the eye, which has a
clear anterior chamber and normal fundi)
Secondary outcome measures
1. Thompson Score (ref. 41) at day 7
2. Head Circumference at 6 months
Outcome measure for Subgroup Analysis
Subgroup analysis of infants with (1) moderately abnormal and (2) suppressed aEEG in
order to determine which of these subgroups is more responsive to hypothermia treat-
530 ment. Griffith General Quotient will be used as outcome measure .
Potential adverse effects to hypothermia may also be consequences of asphyxia, and
thus statistical testing is essential to determine whether cooling may be a contributing
factor. Severe adverse events that in particular may be due to hypothermia will be im-
mediately reported to the Data Safety Monitoring Committee (DSMC) . They are:
← Cardiac arrhythmia
← Severe hypotension despite full inotrope support and volume correction
← Major venous thrombosis not related to an infusion line
← Severe bleeding, e.g. from the lungs or in the brain
Other complications that may occur during the first 7 days of life may include:
υ Electrocardiographic evidence of cardiac arrhythmias or myocardial ischemia or hy-
potension <40mm Hg
550 υ Coagulopathy (clinical bleeding with abnormal clotting studies, consistent with dis-
seminated intravascular coagulation or hepatic coagulopathy)
υ Abnormal renal function (urine output <0.5 ml /kg/hour for >24 hours after birth,
maximum serum creatinine (>0.09 mM).
υ Hyponatremia (<130 mM), hypokalemia (<3.5 mM).
555 υ Bone marrow depression (platelet count <100,000 per mm )
υ Elevated liver enzyme levels (AST >200 IU, ALT >100 IU)
υ Metabolic acidosis (BE <-5) following after entry into study
υ Need for mechanical ventilation
υ Need for nitric oxide
560 υ Need for ECMO
υ Systemic infection (blood, CSF or urine cultures)
υ Hemoconcentration (increase of hematocrit by 20% or more) not associated with
υ Hypoglycemia (<2.6 mmol/L)
565 υ Hypocalcemia (<2 mmol/L) adjusted for albumin levels, or <1.0 mmol/L on ionised
Adverse events related directly to cooling device:
υ Difficulties in temperature control
Randomization will be stratified for hospitals as well as for the severity of asphyxia
(moderate/severe). Before the start of the trial, randomization plans will be established
in the Department of Biometry and Medical Documentation of the University of Ulm,
Germany, for all hospital. The resulting group assignment for each consecutive patient
580 will be concealed in sealed envelopes. The envelopes are identified by
← Title of study : Induced systemic hypothermia...
← Name of the hospital
← moderate / severe asphyxia
585 ← A patient number.
Each participating hospital will receive two piles of envelops, one pile for moderate as-
phyxia and one pile for severe asphyxia.
590 Envelopes have to be used by increasing patient number, i.e. the envelope with the
lowest patient number first.
The envelopes will contain a self adhesive label with title of study, name of the hospital,
the degree of asphyxia (moderate or severe), the patient number and finally the treat-
595 ment (hypothermia or control). This label has to be placed on the case report form on
admission of a patient to the study. Then, a filled out form with the label has to be
transmitted by fax to the regional co-ordinator within 24 hours.
600 Statistical Evaluation
The primary null-hypothesis is: ”The proportion of surviving infants without severe neu-
rodevelopmental handicap at the age of 18-21 months is not reduced by hypothermia”.
The test is one-sided since it is not relevant to confirm statistically whether hypothermia
605 increases the proportions of death or handicap.
The statistical evaluation will be performed on all admitted patients (full sample analysis,
intent to treat analysis). The result will be summarized by a 2 x 2 contingency table (out-
come by group); Fisher’s exact test (level of significance: 5%) will be used to compare
the treatment groups. This test is confirmative.
The statistical evaluation of the data will include all necessary descriptive measures.
The Griffith General Quotient will be compared using a Wilcoxon test for two parallel
groups. All further secondary outcome measures will be evaluated using the appropriate
statistical procedures. These tests are one-sided, too, with a level of significance of 5%.
615 The levels of significance will not be adjusted for multiple testing. Hence, these tests are
only intended for exploration. At regular intervals, interim analyses will be carried out
(see below), their maximum number is 3.
620 Sample size (see APPENDIX 2)
The sample size of 2 x 75 patients has been determined under the following assump-
tions: 60% of the patients suffer from moderate asphyxia, 40% from severe asphyxia.
Further, 75% of the patients with moderate asphyxia and 95$ of the patients with severe
625 asphyxia will be dead or handicapped after 18-21 months in the control group. If 40% of
these cases can be prevented by hypothermia under moderate asphyxia and 10% un-
der severe asphyxia, the overall proportion of dead or handicapped will be 83% in the
control group and 61% in the hypothermia group.15 These assumptions lead to a
sample size of 61 patients per group when testing a one-sided hypothesis at a level of
630 5% with a power of 80% under the given treatment effects. It is realistic to assume that
20% of infants will be lost to follow up. Thus 75 patients will have to be recruited in each
Data Monitoring and Interim Analysis
DATA COLLECTION & MONITORING
640 Data collection and monitoring of study centres is done by the regional co-ordinators.
Data will be passed on to the Department of Biometry and Medical Documentation, Uni-
versity of Ulm, for analysis. Safety and interim analyses will be done when 1/4, 1/2 and
3/4 of the patients are recruited. Severe adverse effects will be reported on the same
day to Ulm. Safety data and Interim analysis will be reviewed by the Safety and Data
645 Monitoring Committee (Pohlandt F, Ulm and Versmold H, Berlin and N.N).
Regional co-ordinators will meet every 6 months to maintain consistency of procedures
when documentation of site visits and sample chart reviews by regional co-ordinators
will be reviewed by the principal investigator.
655 The estimated mortality in the control group is 20% to 30% (assuming a mortality in
moderate asphyxia of about 5% and in severe asphyxia of 60%, further a case mix of
60% moderate and 40% severe asphyxia).The majority of deaths after severe birth as-
phyxia are a consequence of brain damage, and occur within the first week of life. This
means that the study hypothesis, assuming a reduction in adverse outcome (death and
660 handicap) of about 30%, includes an expectation of reducing death rate from 20 to
15%; this is a difference of 5% death before 7 days. The interim analyses will be aimed
at detecting strong evidence against this. Furthermore, the adverse effects of cooling
are recorded within 7 days of life. Safety analysis will compare adverse effects in the
hypothermia and control groups.
Interim analysis will be done when 40, 75 and 115 of the patients in each group have
been recruited and 7 day data is available.
670 If the interim analyses show that it is highly unlikely (p < 0.0025 in the first analysis,
p < 0.005 in the following two interim analyses) that the mortality will be reduced by an
absolute difference 5% or if safety analysis shows that it is highly likely (p-values as
above) that hypothermia is associated with increased number of severe adverse effects,
premature stopping of the trial will be considered by the Data Safety Monitoring Com-
If the trial is stopped prematurely the patients already included in the study will be fol-
lowed up as scheduled by this study protocol.
Final analysis will be based on intent-to-treat and carried out after follow-up is closed for
all patients on study.
The analysis will include
〈 Source data listing
〈 An elementary descriptive analysis of all variables observed
〈 Assessment of data quality achieved
690 〈 Description of study patients
〈 Assessment of drop-outs and comparability of groups
〈 Evaluation of efficacy including scheduled subgroups analysis
〈 Evaluation on adverse events, tolerability and risks of hypothermia
〈 Explorative analysis if further interesting results are supposed
695 〈 Biometrical assessment on validity of study results
In case there will be a serious proportion of drop-outs the most important parts of the
analysis have to be done for all admitted patients (full sample analysis) as well as for
those patients valid for efficacy.
G. Simbruner will file an application at the German Federation for Research (Deutsche
705 Forschungsgemeinschaft) to finance insurance, 1/2 post for a statistician, 1 post for
data monitoring doctor, and up to 10 Lectromed Ceerebral Function Monitors to in-
crease the number of participants in Germany. Other regional co-ordinators will have to
obtain their own funds to fulfil their roles.
1 Finer NN, Robertson CM, Richards RT, Pinnell LE, Peters KL. Hypoxic-ischemic
encephalopahty in term neonates: Perinatal factors and outcome. J Pediatr 1981;
715 98: 112-117
2 Thornberg E. Birth asphyxia: incidence, clinical course and outcome in a Swe-
dish population. Acta Paediatr 1995; 84:927-932
720 3 Robertson CM, Finer NN,Grace MG. School performance of survivors of neonatal
encephalopathy associated with birth asphyxia at term. J Pediatr 1989; 114:
4 Shankaran S, Woldt E, Koepke T, Bedard MP, Nadyal R. Acute neonatal morbid-
725 ity and long-term central nervous system sequelae of perinatal asphyxia in term
infants. Early Hum Dev 1991; 25: 136-148
5 Busto R, Dietrich WD, Globus MYT, Valdes I, Scheinberg P, Ginsberg MD
Small differences in intra-ischemic brain temperature critically determine the ex-
730 tent of ischemic neuronal injury. J Cerebr Blood Flow Metab 1987; 7:
729 - 38
6 Dietrich WD. The Importance of Brain Temperature in Cerebral Injury.
J Neurotrauma 1992; 9: Suppl 2: S-475- 485
7 Thoreson M, Wyatt J. Keeping a cool head, post-hypoxic hypothermia - an old
idea revisited. Acta Paediatr 1997; 86: 1029-33
8 Gelman B, Schleien CL, Lohe A, Kuluz JW. Selective brain cooling in infant pig-
740 lets after cardiac arrest and resuscitation. Crit Care Med 1996; 24: 1009-1017
9 Mellegard P. Changes in human intracerebral temperature in response to differ-
ent methods of brain cooling. Neurosurgery 1992; 31: 671-677
745 10 Simbruner G.Thermodynamic models for diagnosic purposes in the new-born
and fetus; Facultas Verlag, Wien; 1983, ISBN 3-85076-133-9
11 Weinrauch V, Safar P,Tisherman S, Kuboyama K, Radovsky A. Beneficial effects
of mild hypothermia and detrimental effect of deep hypothermia after cardiac ar-
750 rest in dogs. Stroke 1992; 23: 1454-1462
12 Chopp M, Knight R, Tidwell CD, Helpern JA, Brown E Welch KMA. The metabolic
effects of mild hypothermia on global cerebral ischemia and recirculation in the
cat: comparison to normothermia and hyperthermia. J Cereb Blood Flow Metabol
755 1989; 9: 141148
13 Busto R, Globus MYT, Dietrich D, Martinez E, Valdes I,Ginsberg MD. Effect of
mild hypothermia on ischemia-induced release of neurotransmitters and free fatty
acids in rat brain. Stroke 1989; 20: 904-910
14 Coimbra C, Wieloch T. Moderate hypothermia mitigates neuronal damage in the
rat brain when initiated several hours following transient cerebral ischemia. Acta
Neuropathol 1994; 87: 325-331
765 15 Clifton GL, Jiang JY, Lyeth BG, Jenkins LW, Hamm RJ, Hayes RL. Marked pro-
tection by moderate hypothermia after experimental traumatic brain injury. J
Cereb Blood Flow Metab 1991; 1:114-121
16 Armstead WM, Mirro R, Busija DW, Leffler CW. Post-ischemic generation of su-
770 peroxide anion by newborn pig brain. Am J Physiol 1988; 255: H401-403
17 Edwards AD, Yue X, Cox P, Hope PL, Azzopardi D, Squier MV, Mehmet H.
Apoptosis in the brains of infants suffering intrauterine cerebral injury. Pediatr
Res 1997; 42(5) 684-689
18 Colbourne F, Corbett D. Delayed and prolonged post-ischemic hypothermia in
neuroprotective in the gerbil. Brain Research 1994; 654: 265-272
19 Gunn AJ, Gunn TR, Gunning MI, Williams CE, Gluckman PD. Neuroprotection
780 with prolonged head cooling started before post-ischemic seizures in fetal
sheep.Pediatrics 1998; 102 (5): 1098-1106
20 Sirimane ES, Blumberg RM, Bossano E, Gunning M, Edwards AD, Gluckman
PD,Williams CE. The effect of prolonged modification of cerebral temperature on
785 outcome after hypoxic-ischemic brain injury in the infant rat. Pediatr Res 1996; 9:
21 Marion-DW; Penrod-LE; Kelsey-SF; Obrist-WD; Kochanek-PM; Palmer-AM; Wis-
niewski-SR; DeKosky-ST. Treatment of traumatic brain injury with moderate hy-
790 pothermia. N Engl J Med 1997; 336: 540-546
22 Gunn AJ, Gluckman PD, Gunn TR. Selective head cooling in newborn infants
following perinatal asphyxia; a safety study. Pediatrics 1998; 102 : 885 - 892
795 23 Simbruner G, Haberl C, Harrison V, Linley L. Induced brain hypothermia in as-
phyxiated human newborn infants: a retrospective chart analysis of physiological
and adverse effects . Int Care Med 1999; 25:1111-1117
24 Chopp M, Chen H, Dereski MO, Garcia JH. Mild hypothermic intervention after
800 graded ischemic stress in rats. Stroke 1991; 22: 37-43
25 Berger R, Jensen A, Hossmann KA, Paschen W. Effect of mild hypothermia dur-
ing and after transient in vitro ischemia on metabolic disturbances in hippocampal
slices at different stages of development. Dev Brain Res 1998; 105: 67-77
26 Yager JY, Shuaib A, Thornhill J.The effect of age on susceptibility to brain dam-
age in a model of global hemispheric hypoxia-ischmia. Dev Brain Res 1996; 93:
810 27 Cornell HM. Accidental hypothermia. J Pediatr 1992; 120: 671-79. 28
28 Ilievich UM, Spiss CK. Hypothermic therapy for the injured brain. Current Opin-
ions in Anesthesiology 1994; 7:394-400
815 29 Okada M. The cardiac rhythm in accidental hypothermia. J Electrocardiol 1984;
30 Mann TP, Elliot RIK. Neonatal cold injury due to accidental exposure to cold.
Lancet 1957; 1, 229
31 Chadd Ma, Gray OP. Hypothermia and coagulation defects in the newborn. Arch
Dis Child 1972: 41: 819-821
32 Kaplan M, Eidelman AI. Improved prognosis in severely hypothermic newborn
825 infants treated by rapid rewarming. J Pediatr 1984; 105: 470-74
33 Staab BD, Sorensen VJ, Fath JJ, Raman SBK, Horst HM, Obeid FN. Coagulation
defects resulting from ambient temperature-induced hypothermia. J Trauma
1994; 36: 634-8
34 El-Radhi AS, Jawad MH, Ibrahim M, Jamil II. Infection in neonatal hypothermia.
Arch Dis Child 1983; 58 (2): 143-145
35 Shiozaki T, Sugimoto H, Tenada M, Yoshida H, Iwai A, Yoshioka T, Sugimoto T.
835 Effect of mild hypothermia on uncontrollable intracranial hypertension after se-
vere head injury. J Neurosurger 1993; 79: 363-368
36 Bernard SA, Jones BM,Horne MK. Clincal trial of induced hypothermia in coma-
tose survivers of out-of-hospital cardiac arrest. Ann Emerg Med 1997; 30: 146-53
37 Metz C, Holzschuh M, Bein T, Woertgen C, Frey A, Frey I, Taeger K, Brawanski
A. Moderate hypothermia in patients with severe head injury: cerebral and extra-
cerebral effects. J Neurosurgery 1996; 85: 533-541
845 38 Westin B, Nyberg R, Miller JA, Wedenberg E. Hypothermia and transfusion with
oxygenated blood in the treatment of asphyxia neonatorum. Acta paediatr Scand
1962; 51; Suppl 139: 1-80
39 Miller JA, Miller FS, Westin B. Hypothermia in the treatment of asphyxia neona-
850 torum. Biol Neonate 1964; 6: 148-163
40 Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B.
Development and reliability of a system to classify gross motor function in chil-
dren with cerebral palsy. Dev Med Child Neurology 1997; 39: 214-223
41 Thompson CM, Puterman AS, Linley LL, Hann FM, van der Elst CW, Molteno
CD, Malan AF. The value of a scoring system for hypoxic ischaemic encepha-
lopathy in predicting neurodevelopmental outcome. Acta Paediatr 1997; 86:
42 al Naqeeb N, Edwards AD, Cowan FM, Azzopardi D. Assessment of Neonatal
Encephalopathy by Amplitude-intergrated Electroencephalography. Pediatrics
1999; 103; 1263-1271
43 Hellström-Westas L, Rosén I, Svenningsen NW (1995) Predictive value of
early continuous amplitude integrated EEG recordings on outcome after severe
birth asphyxia in full term infants. Arch Dis Child 72: F34-F38
870 44 Toet MC, Eken P, Groenendaal F, de Vries LS Comparison of amplitude
integrated EEG in birth asphyxiated term neonates between 3 and 6 hours
after birth (Abstr 1902, Neurology; Ped Res 1998; 43, Part 2 of 2)
45 Lamblin MD, Andre M, Challamel MJ, Curzi-Dascalova L, dÁllest AM, De Giovanni
E , Moussalli-Salefranque F, Navelet Y, Plouin P, Radvanyi-Bouvet MF, Samson-
875 Dollfus D, Vecchierini-Blineau MF. Electroencephalographie du nouveau-ne
premature at a term. Aspects maturativs et glossaire. Neurophysiol Clin 1999; 29:
123 - 219
46 Thoresen M and Wyatt J. Review article . Acta Paediatr 1997; 86: 1029-33
880 Keeping a cool head, post-hypoxic hypothrmia-an old idea revistied
(References 29- 34)
47 Thoresen M, Cooling the newborn aftrer asphyxia - physiological and
experimental background and its clinical use. Semin Neonatol 2000; 5:61-73
48 Thoresen M, Satas S, Loberg EM, Lindgren C, Acolet D, Steen PA, Haug E,
Whitelaw A. Pediatr Res 1999; 45: 46 A
895 Procedures and definitions for neurological assessment, aEEG and EEG
Assessment of Neurological Signs
Neurological signs are observed and scored according to Thompson et al (41).The
score consists of a clinical assessment of nine signs. Each sign is scored from 0 to 3
and the score for each day is totalled. The higher the score the more severely affected
the infant. The maximum possible score on any day is 22. The score is equally applica-
905 ble to ventilated infants . It cannot be applied to paralyzed infants.
Sign 0 1 2 3
910 Tone normal hyper hypo flaccid
LOC normal hyperalert, stare lethargic comatouse
Fits none < 3 per day > 2 per day
Posture normal fisting, cylcing strong distal flexion decerebrate
Moro normal partial absent
915 Grasp normal poor absent
Suck normal poor absent ± bites
Respir normal hyperventilation brief apnea IPPV (apnea)
Fontanell normal full, not tense tense
Recording of aEEG and Standard EEG
The aEEG will be recorded with a Lectromed Cerebral Function Monitor and the use of
needle electrodes inserted at an exact distance of 5 cm apart from each other at the
925 temples. Different distances result in different voltage (Personal communication: Hell-
ström-Westas L, Blennow M). The recording speed is 1mm/min. At least one half hour
recording is required, latest between 5.0 and 5.5 hours of age. A 30 min decrease of
lower voltage margine below 5uV must not be associated with sleep cylces, manipula-
tions or drug administration.
The Standard EEG is recorded according to the International 10-20 classification.
Classification of aEEG for Inclusion Criteria
The classification of the aEEG is based on the publication of Niran al Naqeeb et al.
(ref 42 : Pediatrics 1999; 103; 1263-1271). It yields three subgroups: normal aEEG,
moderately abnormal aEEG and suppressed aEEG. Moderately abnormal aEEG desig-
nates mildly to moderately asphyxiated new-born and suppressed aEEE severely as-
940 phyxiated new-borns. This classification is used for subgroup analysis. Patients with the
unlikely aEEG combination of upper margin < 10 uV and lower margin >5uV will remain
unclassified and excluded from the study.
945 Classification of standard EEG for Inclusion criteria
The classification of the standard EEG is based on the publication of Lamblin MD et al.
(ref 45: Neurophysiol Clin 1999; 29: 123 - 219)
950 Definition of normal EEG:
Continuous , no intervals > 3 sec and no amplitudes < 10 uV
Definition of abnormal EEG:
Continous low voltage < 25 uV or discontinuous (burst supression)
955 see exact definition 4.1 , 4.2 and 4.4 , 4.5 in article of Lamblin et al.
Sampling rate: Every 5 min a time sample of 20 sec long tracing
Scientific basis for inclusion criteria, classification into subgroups and
sample size calculations.
This study includes all asphyxiated new-borns whose aEEG or standard EEG is not
970 normal at any time within the first six hours of age. Infants with a normal aEEG or Stan-
dard EEG, not included into the study, may later turn out to have an neurodevelopmen-
tal impairment. The false negative rate (normal EEG, but abnormal outcome) might
range from 4% to 15% (42 - 44). The study population will contain mild to moderate en-
cephalopathy and severe encephalopathy. These two subgroups will be classified be-
975 fore the intervention and within the first 6 hours of age according to their aEEG or stan-
dard EEG (see APPENDIX 1) .
The event rate is defined as death or neurodevelopmental impairment of survivors. De-
pending on the severity, asphyxia causes a certain rate of neurodevelopmental impair-
ments. The table shows the event rates of ”death and neurodevelopmental impairment
”in dependence of the initial severity classified according to aEEG into the two sub-
985 groups. Estimated from data from Hellström-Westas et al, Toet et al and AlNaqeeb et al.
(42 - 44).
Correlation of ampliutde-integrated EEG to neurological outcome
Severity Author Nr Event rate (%) Event rate (%)
Disabilty and Death No Disability
Normal al Naqueeb 9 0 (0%) 9 (100%)
995 Hellström 26 1 (4%) 25 (96%)
Toet 26 4 (15%) 22 (85%)
Moderate al Naqeeb 17 13 (75%) 4 (25%)
abnormal Hellström 14 11 (77%) 3 (23%)
1000 aEEG Toet 13 10 (77%) 3 (23%)
Suppressed al Naqeeb 12 12 (100%) 0 (0 %)
1005 aEEG Hellström 5 5 (100%) 0 (0%)
Toet 5 5 (100%) 0 (0%)
Summarized Results of aEEG Studies
1010 No disability Disability Nr.
Normal aEEG 56 5 61
Abnormal aEEG 10 56 66
66 61 239
Sensitivity 56/61 = 92 % ; Specificity 56/66 = 85%
1020 Correlation of standard EEG to neurological outcome
(analyzed according to criteria of Lamblin MD et al., to be published d ´Allest AM et al.)
No disability Disability Nr.
Normal EEG 128 (96%) 5 (4%) 133 (55.6 %)
Mod abn EEG 17 (54%) 14 (46%) 31 (13.0 %)
1030 Severe abn EEG 2 (3%) 73 (97%) 75 (31.4 %)
147 30 239
1035 Summarized Results of Standard EEG
No disability Disability Nr.
1040 Normal EEG 128 5 133
Abnormal EEG 19 87 106
147 92 239
Sensitivity 87/92 = 95 % ; Specificity 128/147 = 87 %
These data on aEEG and standard EEG on neurodevelopmental outcome demonstrate:
(i) that aEEG and standard EEG have a similarly high predicitve power (92% vs 95%
sensitivity and 85% vs 87% specificity). Consequently both methods are valid for the
1050 inclusion of asphyxiated infants.
(ii) that the ratio of moderate to severe aEEG findings is 66 % and 33% respectively in
the compiled aEEG studies (ref 42-44) and the ratio of moderate to severe in the stan-
dard EEG Data (see above) is 30% vs 70%.
Consequently an overall ratio of 60% moderate and 40% severe asphyxia was assumed
1055 for sample size calculation and
iii) because of the lack of congruence of subgroups defined by aEEG and standard
EEG, subgroup analysis will be done only on patients with aEEG inclusion criteria.
1060 Treatment effect
In six new-born animal studies the neuroprotection (expressed as reduction in % cell
damage or abnormal neurobehavior) of mild to moderate hypothermia starting within
30 min after the ischemic-hypoxic insult varied between 25 to 80% (the neuroprotective
1065 effect was > 50%, when those studies where hypothermia was induced only for <3 hrs,
were excluded (46)). No data for the treatment effect of asphyxiated human new-borns
are available. The study population will contain infants with mild to moderate encepha-
lopathy. In animal experiments hypothermia has been shown to be more effective in
mild to moderate asphyxia than in severe to fatal asphyxia (Chopp M et al. Mild hypo-
1070 thermic intervention after graded ischemic stress in rats. Stroke 1991; 22: 37-43).
Gluckman et al in the Olympic Medical Protocol assumed a 30 % reduction of neurode-
velopmental impairment and death (an event rate of 70% in the control and 49% in the
intervention group) in a group of mixed (moderately and severely) asphyxiated new-
borns. We thus assumed a 40% reduction (less than the 50% in animal experiments,
1075 but more than the 30% for the mixed group) for the mildly to moderately and 10% (less
than the mixed group) for the severely asphyxiated group.
Specifications for cooling mattress and aEEG device
Cerebral Function Monitor (CFM)
The CFM to be used for the study is the one from Lectromed or proven equivalent.
LECTROMED Cerebral Function Monitor
1090 Lectromed MT2-5330 CFM System
Representative in Germany:
FBI Fred Berninger Importe OHG
1095 D-82024 Taufkirchen, Germany
Tel.: + 49 89 61 453 453 or +49 161 2832755
Fax.: + 49 89 61 453 453
e-mail > BERNIMPORT@AOL.com
The cooling device to be used for the study is the one of TEC.COM GMBH. It consists
of an apparatus which provides a perfusion flow of a temperature regulated fluid and a
1105 mattress. A simpler version Tecovit 200 for NICU use and transport, with battery 12 V
powering, is available.
Cooling device Tecotherm TS med 200 (about 3200 Euro) , size 420 x 190 x 350 mm,
1110 ca 10 kg; Temperatue range : 5 - 42°C ; hand controlled
Tecovit 200 (about 1750 Euro)
plus CSZ Cooling matrass, rectangular, cleanable surface, ca.80 x 60 cm (about
TEC.COM GMBH Prof Dr K Berndt e-mail >email@example.com<
Product Manager OR >SCHOEPKE:firstname.lastname@example.org
Böllberger Weg 170
D - 06128 Halle/Saale, Germany
1120 Tel.: + 49 (0) 345 – 120 52 04
Fax.: + 49 (0) 345 – 120 52 11
1125 Monitoring Schedule
Time adm before 3 12 24 48 72 80 hrs
1130 CerFunction aEEG x----- continous------x x x x cont x
Rect Temp ( Thermom ) x x -----------------hourly----------------------- x
Cooling Fluid Temp x x -----------------hourly----------------------- x
Environm Temp x x x x x x x x
Blood Pressure x x -----------------hourly----------------------- x
Heart rate x x -----------------hourly----------------------- x
Breathing rate x x -----------------hourly----------------------- x
SpO2 x x -----------------hourly----------------------- x
1140 PtcCO2 x x -----------------hourly----------------------- x
Respir Variables x x x x x x x x
Urine output (3hrs) x x x x x x x x
blood gases x x x x x x x x
1145 glucose x x x x x x x x
Clinical Examination x x x x x x x
Neurol Examination x x x x x x x
Ultasound Imaging x
Organ Failure x x x x
1155 electrolytes x x x x
hemoglobin x x x x
coagulation x x x x
infection screen x x x x
kidney function x x x x
amylse x x
endocrine x x
lactate x x
lumbal x - between - x
Blood S-100, NSE x - between - x
Time adm before 3 12 24 48 72 80 hrs